Torrent Pharmaceuticals’ Board of Directors approved the Audited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter and nine months ending December 31, 2025. The company reported strong standalone net profit growth of 26% YoY for the quarter. Furthermore, the Board recommended an interim dividend of ₹29 per equity share, payable on or around March 6, 2026. Consolidated revenue grew 18% YoY for the quarter, driven by robust branded business performance.
Torrent Pharma Reports Q3 FY26 Financial Performance
Torrent Pharmaceuticals Limited announced the results of its Board meeting held on February 13, 2026, where the financial outcomes for the third quarter and nine months ended December 31, 2025, were approved. The results highlight robust growth across key metrics, underpinned by the recent acquisition of a stake in JB Chemicals & Pharmaceuticals.
Key Standalone Financial Highlights (Q3 FY26 vs. Q3 FY25)
The standalone performance demonstrated significant year-over-year (YoY) improvements:
- Revenue from operations for the quarter stood at ₹2,599 crores, compared to ₹2,380 crores in Q3 FY25.
- Total Income reached ₹2,591 crores, up from ₹2,380 crores YoY.
- Net Profit for the period grew substantially to ₹577 crores, up from ₹485 crores in the previous corresponding quarter.
- Basic and Diluted Earnings Per Share (EPS) for the quarter were ₹17.04, against ₹14.33 YoY.
Consolidated Performance Snapshot
The consolidated results also reflected strong growth, particularly in Net Profit After Tax (PAT), which surged by 26% YoY for the quarter.
- Consolidated Revenue for Q3 FY26 was ₹3,303 crores, an 18% increase over Q3 FY25’s ₹2,809 crores.
- Operating EBITDA margin remained strong at 33% (Q3 FY26).
- Consolidated PAT for the quarter was ₹635 crores, marking a 26% increase from ₹503 crores YoY.
- The Gross Margin stood firm at 76% for the quarter.
Interim Dividend Recommendation
In a significant announcement, the Board recommended an interim dividend of ₹29 per equity share (representing 580% on the ₹5 face value). This dividend is scheduled to be paid or dispatched on or around March 6, 2026.
Strategic Developments: JB Pharma Acquisition
The company confirmed that the acquisition of a controlling stake in JB Chemicals & Pharmaceuticals Limited (JB Pharma) has been completed, with control effective from January 21, 2026. Regulatory and statutory fees related to this acquisition have been recognized as Exceptional Items.
The merger scheme for JB Pharma is currently in the process of obtaining necessary regulatory approvals before filing with the National Company Law Tribunal (NCLT).
Geographic Performance Highlights (9M FY26)
The company provided a breakdown of performance across key geographies for the first nine months of FY26:
- India: Revenues reached ₹5,430 crores, showing a 12% increase. IPM growth in the secondary market was 10%.
- Brazil: Revenues were up 27% (or 10% in Constant Currency), reaching ₹907 crores for the nine months.
- United States: Revenues for 9M FY26 totaled ₹967 crores, marking a 21% growth (or 16% in Constant Currency).
- Germany: Revenues grew by 7% (or a 3% decline in Constant Currency) to ₹916 crores for the nine-month period.
Auditor’s Confirmation
The Independent Auditors, BSR & Co. LLP, issued an unqualified opinion on the standalone results, confirming that the figures present a true and fair view in conformity with applicable accounting standards. A separate Limited Review Report was issued for the consolidated results.
Source: BSE
